FBLN2
FBLN2 (Fibulin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Bladder & urothelial cancer, Hepatocellular carcinoma and 4 more.
Overview
Its binding to fibronectin and some other ligands is calcium dependent. May act as an adapter that mediates the interaction between FBN1 and ELN.
IntOGen calls it a driver in 8 cohorts (2 activating, 5 loss-of-function), covering Bladder Urothelial Carcinoma, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Neuroblastoma, Pancreatic Adenocarcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FBLN2 (Fibulin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Bladder & urothelial cancer, Hepatocellular carcinoma and 4 more.
- 1 · What it is
FBLN2 (Fibulin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Bladder & urothelial cancer, Hepatocellular carcinoma and 4 more.
- 2 · What goes wrong in cancer
Its binding to fibronectin and some other ligands is calcium dependent. May act as an adapter that mediates the interaction between FBN1 and ELN.
- 3 · How drugs use it
No product in this corpus aims at FBLN2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:3601 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P98095 (protein name, function text, keywords and locations (REST API)); IntOGen FBLN2 (driver in 8 cohorts (Act 2, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Its binding to fibronectin and some other ligands is calcium dependent. May act as an adapter that mediates the interaction between FBN1 and ELN. Location: Secreted, extracellular space, extracellular matrix (UniProt). Locus 3p25.1 (HGNC).
- Pancreatic ductal adenocarcinoma: IntOGen driver in 2 cohorts (PAAD)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Prostate cancer: IntOGen driver in 1 cohort (PRAD)
- Biliary tract cancer: IntOGen driver in 1 cohort (CHOL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FBLN2" OR ABSTRACT:"FBLN2" OR TITLE:"fibulin 2" OR ABSTRACT:"fibulin 2" OR TITLE:"Fibulin-2" OR ABSTRACT:"Fibulin-2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FBLN2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCTNNA2
Shares Biliary tract cancer (cholangiocarcinoma), Hepatocellular carcinoma, IntOGen, Head and neck squamous cell carcinoma.
- TargetZNF429
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, Hepatocellular carcinoma, IntOGen.
- TargetN4BP2
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, Hepatocellular carcinoma, IntOGen.
- TargetETV4
Shares Neuroblastoma (paediatric), IntOGen, Pancreatic ductal adenocarcinoma, Prostate cancer.
- TargetELF3
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, IntOGen.
- TargetMYO5A
Shares Neuroblastoma (paediatric), Hepatocellular carcinoma, IntOGen.
- TargetRBM10
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer, IntOGen, Pancreatic ductal adenocarcinoma.
- TargetMYH11
Shares Biliary tract cancer (cholangiocarcinoma), IntOGen, Head and neck squamous cell carcinoma, Prostate cancer.